Octreotide enhances portal pressure reduction induced by propranolol in cirrhosis: A randomized, controlled trial

American Journal of Gastroenterology

Volumn 102, Issue 10, 2007, Pages 2206-2213

  Vorobioff, Julio D ^a,b   Ferretti, Sebastián E ^b   Zangroniz, Pedro ^b   Gamen, Marcelo ^a   Picabea, Eduardo ^a   Bessone, Fernando O ^b   Reggiardo, Virginia ^b   Diez, Ana R ^b   Tanno, Mario ^b   Cuesta, Cristina ^c   Tanno, Hugo E ^b  

^a Sanatorio Parque   (Argentina)

^b Hospital Centenario de Rosario   (Argentina)

^c UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE; PLACEBO; PROPRANOLOL;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SCREENING; FEMALE; HUMAN; LIVER CIRRHOSIS; LONG TERM CARE; MALE; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC BETA-ANTAGONISTS; DRUG ADMINISTRATION SCHEDULE; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HEART RATE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; OCTREOTIDE; PORTAL PRESSURE; PROPRANOLOL;

EID: 34848912219     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.01390.x     Document Type: Article

References (44)

1. Jenkins SA, Barter JN, Corbett WA, et al. The effects of a somatostatin analogue SMS 201-995 on hepatic haemodynamics in the cirrhotic rat. Br J Surg 1985 72 : 864 7.
2. Jenkins SA, Barter JN, Corbett WA, et al. Effects of a somatostatin analogue SMS 201-995 on hepatic haemodynamics in the pig and on intravariceal pressure in man. Br J Surg 1985 72 : 1009 12.
3. Jenkins SA, Barter JN, Snowden S, et al. The effect of somatostatin and SMS 201-995 on hepatic and systemic hemodynamics in patients with cirrhosis and portal hypertension. Fibrinolysis 1988 2 : 48 50.
4. Pringle SD, McKee RF, Garden OJ, et al. The effect of a long-acting somatostatin analogue on portal and systemic haemodynamics in cirrhosis. Aliment Pharmacol Ther 1988 2 : 451 9.
5. Lamberts SWJ, Van Der Lely AJ, De Herder WW, et al. Octreotide. N Engl J Med 1996 334 : 246 54.
6. Hwang SJ, Lin HC, Chang CF, et al. A randomized controlled trial comparing octreotide and vasopressin in the control of acute esophageal variceal hemorrhage. J Hepatol 1992 16 : 320 5.
7. McKee RF, Garden OJ, Anderson JR, et al. A comparison of SMS 201-995 and oesophageal tamponade in the control of acute variceal haemorrhage. HPB Surg 1992 6 : 7 17.
8. Silvain C, Carpentier S, Sautereau D, et al. Terlipressin plus transdermal nitroglycerin vs. octreotide in the control of acute bleeding from esophageal varices: A multicenter randomized trial. Hepatology 1993 18 : 61 5.
9. Besson I, Ingrand P, Person B, et al. Sclerotherapy with or without octreotide for acute variceal bleeding. N Engl J Med 1995 333 : 555 60.
10. Jenkins SA, Shields R, Davies M, et al. A multicentre randomised trial comparing octreotide and injection sclerotherapy in the management and outcome of acute variceal haemorrhage. Gut 1997 41 : 526 33.
11. Burroughs AK. Double blind RCT of 5 day octreotide versus placebo, associated with sclerotherapy for trial failures. Hepatology 1996 24 (Suppl 352A.
12. Corley DA, Cello JP, Adkisson W, et al. Octreotide for acute esophageal variceal bleeding: A meta-analysis. Gastroenterology 2001 120 : 946 54.
13. D'Amico G. First meta-analysis of octreotide for variceal bleeding. A lost opportunity. J Hepatol 2002 36 : 574 7.
14. Escorsell A, Bandi JC, Andreu V, et al. Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology 2001 120 : 161 9.
15. McCormick PA, Biagini MR, Dick R, et al. Octreotide inhibits the meal-induced increases in the portal vein pressure of cirrhotic patients with portal hypertension: A double-blind, placebo-controlled study. Hepatology 1992 16 : 1180 6.
16. Albillos A, Rossi I, Iborra J, et al. Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension. J Hepatol 1994 21 : 88 94.
17. Vorobioff J, Gamen M, Kravetz D, et al. Effects of long-term propranolol and octreotide on postprandial hemodynamics in cirrhosis: A randomized, controlled trial. Gastroenterology 2002 122 : 916 22.
18. Villanueva C, Ortiz J, Miñana J, et al. Somatostatin treatment and risk stratification by continuous portal pressure monitoring during acute variceal bleeding. Gastroenterology 2001 121 : 110 7.
19. Kravetz D, Bosch J, Arderiu MT, et al. Effects of somatostatin on splanchnic hemodynamics and plasma glucagon in portal hypertensive rats. Am J Physiol 1988 254 : G322 8.
20. Pizcueta MP, García-Pagán JC, Fernández M, et al. Glucagon hinders the effects of somatostatin on portal hypertension. A study in rats with partial portal vein ligation. Gastroenterology 1991 101 : 1710 5.
21. McCormick PA, Chin J, Greenslade L, et al. Cardiovascular effects of octreotide in patients with hepatic cirrhosis. Hepatology 1995 21 : 1255 60.
22. Chatila R, Ferayorni L, Gupta T, et al. Local arterial vasoconstriction induced by octreotide in patients with cirrhosis. Hepatology 2000 31 : 572 6.
23. Sieber C, Mosca PG, Groszmann RJ. Effect of somatostatin on mesenteric vascular resistance in normal and portal hypertensive rats. Am J Physiol 1992 262 : G274 7.
24. Wiest R, Tsai M, Groszmann RJ. Octreotide potentiates PKC-dependent vasoconstriction in splanchnic arteries in portal-hypertensive and control rats. Gastroenterology 2001 120 : 975 83.
25. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: An evidence-based approach. Semin Liv Dis 1999 19 : 475 505.
26. García-Pagán JC, Escorsell A, Moitinho E, et al. Influence of pharmacological agents on portal hemodynamics: Basis for its use in the treatment of portal hypertension. Semin Liv Dis 1999 19 : 427 38.
27. Hillon P, Lebrec D, Muñoz C, et al. Comparison of the effects of a cardioselective and a non-selective b-blocker on portal hypertension in patients with cirrhosis. Hepatology 1982 2 : 528 31.
28. Kroeger RJ, Groszmann RJ. Effects of selective blockade of beta 2-adrenergic receptors on portal and systemic hemodynamics in a portal hypertensive rat model. Gastroenterology 1985 88 : 896 900.
29. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973 60 : 646 9.
30. Groszmann RJ, Glickman M, Blei AT, et al. Wedged and free hepatic venous pressure measured with a balloon catheter. Gastroenterology 1979 76 : 251 8.
31. Garcia Pagan JC, Navasa M, Bosch J, et al. Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis. Hepatology 1990 11 : 230 8.
32. Albillos A, García-Pagan JC, Iborra J, et al. Propranolol plus prazosin compared to propranolol plus isosorbide-5-mononitrate in the chronic treatment of portal hypertension. Gastroenterology 1998 115 : 116 23.
33. Merkel C, Marin R, Enzo E, et al. Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Lancet 1996 348 : 1677 81.
34. García-Pagan JC, Morillas R, Bañares R, et al. Propranolol plus placebo versus propranolol plus isososrbide-5-mononitrate in the prevention of a first variceal bleed: A double-blind RCT. Hepatology 2003 37 : 1254 6.
35. Bernard-Chabert B, Sauerbruch TT, Gin-Ho L, et al. Prevention of rebleeding. In : Portal hypertension IV. Proceedings of the Fourth Baveno International Consensus Workshop on methodology of diagnosis and treatment. de Franchis R, ed. Oxford, UK : Blackwell Publishing, 2005 : 262 84.
36. McCormick PA, Dick R, Siringo S, et al. Octreotide reduces azygos blood flow in cirrhotic patients with portal hypertension. Eur J Gastroenterol Hepatol 1990 2 : 489 92.
37. McCormick PA, Seifalian AM, Stansby G, et al. Superior mesenteric artery blood flow in man measured with intra-arterial Doppler catheters: Effect of octreotide. J Hepatol 1993 17 : 20 7.
38. Harris AG. Somatostatin and somatostatin analogues: Pharmacokinetics and pharmacodynamic effects. Gut 1994 35 (Suppl 3 S1 4.
39. Anthony LB. Long-acting formulations of somatostatin analogues. Ital J Gastroenterol Hepatol 1999 31 (Suppl 2 S216 8.
40. Merkel C, Sacerdoti D, Bolognesi M, et al. Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the b-blocker alone. Hepatology 1997 26 : 34 9.
41. Vorobioff J, Picabea E, Gamen M, et al. Propranolol compared with propranolol plus isosorbide dinitrate in portal-hypertensive patients. Long-term hemodynamic and renal effects. Hepatology 1993 18 : 477 84.
42. Abraldes JG, Tarantino I, Turnes J, et al. Hemodynamic response to pharmacological treatment of portal hypertensión and long-term prognosis of cirrhosis. Hepatology 2003 37 : 902 8.
43. D'Amico G, Garcia-Pagan JC, Luca A, et al. Hepatic vein pressure gradient reduction and pevention of variceal bleeding in cirrhosis: A systematic review. Gastroenterology 2006 131 : 1611 24.
44. Bellis L, Berzigotti A, González-Abraldes J, et al. Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis. Hepatology 2003 37 : 378 84.